Vaishali Sanchorawala, MD

In this insightful discussion, Vaishali Sanchorawala, a leading expert in amyloidosis from Boston University, and Ashutosh Wechalekar, a prominent hematologist from University College London, delve into the cutting-edge findings presented at the recent ASH meeting. They highlight breakthrough results from the ANDROMEDA trial, emphasizing the effectiveness of daratumumab VCD for AL amyloidosis treatment. The duo also explores advancements in risk stratification and the promising role of measurable residual disease and CAR T-cell therapy in enhancing patient care.

Experts Mario Nuvolone, Vaishali Sanchorawala, and Patrick Hagen discuss the critical importance of early diagnosis in AL amyloidosis, ongoing clinical trials like Venetoclax and Exazomib, patient selection for SCT, and challenges in managing relapsed refractory amyloidosis.

Guests Angela Dispenzieri, MD, Paolo Lopedote, MD, and Vaishali Sanchorawala, MD discuss unmet needs in AL amyloidosis, including early diagnosis and optimal treatment strategies. They explore the prevalence and impact of CHIP in amyloidosis patients, as well as alternative treatment options for those who cannot undergo stem cell transplantation. The speakers also discuss refining hematologic response criteria and assessing residual disease in AL amyloidosis treatment.